Vaxcyte (PCVX)Director sold ~$89K
Teri Loxam, Director at Vaxcyte, sold ~$89K of Vaxcyte shares.
- ~$89K
- Approx. value · 1,043 sh @ $85.29
- 9,683
- Holds after · shares reported
- Traded
- Jan 15, 2025
- Filed
- Jan 17, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Nov 18, 2024Insider · 1 personInsiders: 3 sales (~$687K)
- Dec 2, 2024Insider · 2 peopleInsiders: 6 sales (~$2.1M)
- Dec 5, 2024Insider · 1 personInsiders: 3 sales (~$457K)
- Dec 9, 2024Insider · 1 personInsiders: 4 sales (~$218K)
- Dec 18, 2024Insider · 1 personInsiders: 4 sales (~$710K)
- Jan 2, 2025Insider · 1 personInsiders: 3 sales (~$669K)
- Jan 6, 2025Insider · 1 personInsiders: 3 sales (~$428K)
- Jan 15, 2025 · this disclosureInsiderDirector sold ~$89K of PCVX shares in the open market
What came next
- Jan 15, 2025Insider · 1 personInsiders: 7 sales (~$443K)
- Jan 21, 2025Insider · 1 personInsiders: 3 sales (~$692K)
- Feb 3, 2025Insider · 1 personInsiders: 3 sales (~$690K)
- Feb 5, 2025Insider · 1 personInsiders: 5 sales (~$450K)
- Feb 18, 2025Insider · 1 personInsiders: 2 sales (~$671K)
- Mar 3, 2025Insider · 1 personInsiders: 2 sales (~$586K)
- Mar 5, 2025Insider · 1 personInsiders: 3 sales (~$354K)
- Mar 5, 2025CongressDisclosed sale of PCVX — reported range $15,001 - $50,000
- Apr 14, 2025CongressDisclosed purchase of PCVX — reported range $1,001 - $15,000
- Apr 15, 2025CongressDisclosed purchase of PCVX — reported range $1,001 - $15,000
- Apr 28, 2025CongressDisclosed purchase of PCVX — reported range $1,001 - $15,000
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Vaxcyte
For Vaxcyte, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 9 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PCVX page.
Other recent filings by Teri Loxam, Director
- SEC Form 4 at Vaxcyte (PCVX)Jan 17, 2025
- SEC Form 4 at Vaxcyte (PCVX)Jan 17, 2025
- SEC Form 4 at Vaxcyte (PCVX)Jan 17, 2025
- SEC Form 4 at Vaxcyte (PCVX)Jan 17, 2025
- SEC Form 4 at Vaxcyte (PCVX)Jan 17, 2025
The full history of Teri Loxam, Director is on the profile page.
How this filing works
Other disclosures at Vaxcyte
- SEC Form 4Oct 8, 2026
- SEC Form 4Oct 8, 2026
- SEC Form 144Oct 5, 2026
- SEC Form 144Oct 5, 2026
- SEC Form 4Oct 3, 2026
- SEC Form 4Oct 3, 2026
Everything OQRO holds on this company is on its PCVX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
